MSL
TPTX

Mackay Shields LLC’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Mackay Shields LLC’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-15,000
Closed -$1.42M – 1444
2021
Q1 		$1.42M Sell
15,000
-9,600
-39% -$1.14M 0.01% 898
2020
Q4 		$3M Buy
24,600
+2,200
+10% +$241K 0.02% 666
2020
Q3 		$1.96M Sell
22,400
-2,300
-9% -$160K 0.01% 796
2020
Q2 		$1.6M Buy
24,700
+3,300
+15% +$190K 0.01% 855
2020
Q1 		$956K Buy
+21,400
New +$1.14M 0.01% 960

Other funds holding TPTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Mackay Shields LLC's TPTX Position: Q2 2021 in Review

Mackay Shields LLC sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2021, closing a stake of 15,000 shares — an estimated $1.42M sold.

Mackay Shields LLC first reported a position in TPTX in Q1 2020 and held it in 5 quarters. The position peaked at $3M in Q4 2020. 190 funds tracked by Wall St. Rank hold TPTX as of Q2 2021.

  • Mackay Shields LLC reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Mackay Shields LLC sold 15,000 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $1.42M.
  • Mackay Shields LLC first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q1 2020 and held it in 5 quarters.
  • Mackay Shields LLC's Turning Point Therapeutics, Inc. Common Stock position peaked at $3M in Q4 2020.
  • 190 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Mackay Shields LLC's 13F filing for Q2 2021, filed 13 Aug 2021.